Abstract
We test the hypothesis of increasing prevalence of low-dose antipsychotic use (300 mg/d chlorpromazine-equivalent) in East Asia and examine clinical correlates of conservative dosing. Rates of low-dose antipsychotic prescription were determined for 4535 patients with DSM-IV diagnosis of schizophrenia in six East Asian countries and territories, with comparisons analysed for 2004 vs. 2001. Between 2001 (n=2399 subjects) and 2004 (n=2136 subjects), prescription rates for low doses of antipsychotic drugs (APDs) increased from 24.8% to 44.0% (p<0.001). Low doses were more likely among older patients (p=0.005), during first-lifetime hospitalizations (p<0.001), and among patients with less prominent delusions, hallucinations or disorganized speech (all p<0.05). Multivariate modelling indicated that low doses were strongly associated with older age, first admission, sampling year (2004>2001), less use of antipsychotic polytherapy (all p<0.001) and depot antipsychotics (p=0.009). Conservative dosing of APDs was increasingly prevalent in East Asia. Our findings suggest characteristics of patients who may be particularly likely to require low antipsychotic doses.
References
Jan 1, 1988·Archives of General Psychiatry·R J BaldessariniM H Teicher
May 1, 1997·Archives of General Psychiatry·N R SchoolerM G Woerner
Feb 7, 1998·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J M KaneN R Schooler
Mar 21, 1998·Schizophrenia Bulletin·A F Lehman, D M Steinwachs
Mar 30, 2000·The American Journal of Psychiatry·S KapurS Houle
Jun 10, 2000·The Journal of Clinical Psychiatry·J T WalkupS Hansell
Feb 4, 2003·The American Journal of Psychiatry·Lieuwe de HaanDon Linszen
Jun 26, 2003·The Journal of Clinical Psychiatry·Scott W Woods
Jul 17, 2004·British Journal of Clinical Pharmacology·Kang SimChay H Tan
Oct 7, 2004·Pharmacopsychiatry·K SimC H Tan
Jun 16, 2005·Human Psychopharmacology·Franca CentorrinoRoss J Baldessarini
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Nov 12, 2005·Journal of Clinical Psychopharmacology·Gary RemingtonShitij Kapur
Jan 21, 2006·Acta Psychiatrica Scandinavica·R M CarnahanE A Chrischilles
Oct 3, 2006·International Clinical Psychopharmacology·Corrado BarbuiMichele Tansella
Oct 31, 2006·Schizophrenia Research·Christoph U CorrellPeter Manu
May 24, 2007·International Clinical Psychopharmacology·Corrado BarbuiLuigi Grassi
Sep 11, 2007·Psychological Medicine·A ThompsonG Harrison
Sep 13, 2007·Current Medical Research and Opinion·Robert J ValuckUNKNOWN Medicaid Pharmacotherapy Research Consortium
Sep 13, 2007·Molecular Psychiatry·H A Nasrallah
Sep 28, 2007·Clinical Pharmacology and Therapeutics·L Bertilsson
Feb 5, 2008·Schizophrenia Research·Rajiv TandonUNKNOWN Section of Pharmacopsychiatry, World Psychiatric Association
Citations
Feb 4, 2012·International Psychogeriatrics·Yu-Tao XiangChay-Hoon Tan
Aug 23, 2012·BMC Psychiatry·Giuseppe RossiAndrea Rossi
May 26, 2010·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Cheng-Ta LiYa-Mei Bai
Oct 11, 2015·Psychiatry Research·Chien-Yeh ChiuMau-Sun Hua
Sep 15, 2021·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Naotaka Shinfuku